KT-621 Achieved Deep STAT6 Degradation in Blood and Skin
Degradation Maintained for 28 Days Across Both Dose Cohorts

                                   Median STAT6 Degradation in Blood                                                 Median STAT6 Degradation in Skin
                                             Method: Flow Cytometry                                                        Method: Targeted Mass Spec




   % STAT6 Change from Baseline                                                       % STAT6 Change from Baseline
                                               KT-621 100 mg QD (n = 8)1
                                               KT-621 200 mg QD (n = 10)1




         Median (Q1, Q3)                                                                    Median (Q1, Q3)


                                            ON TREATMENT
                                                                                                                       KT-621 100 mg QD     KT-621 200 mg QD
                                                                                                                             (n = 9)2             (n = 11)2
                                                  Time (Day)

                  •               Median STAT6 degradation of 98% in blood in both dose groups maintained throughout the treatment period
                  •               Deep skin degradation of 94% in both dose groups with multiple patients’ STAT6 levels below the LLOQ (lower
                                  limit of quantification)

                                                                                                                                                               25
